1. Introduction {#sec1-marinedrugs-18-00367}
===============

Microalgae are fast growing autotrophic organisms. They use light energy and carbon dioxide for the photosynthetic biomass production with higher efficiency compared to plants. There are over 300,000 species of microalgae, of which only around 30,000 (10%) of them have been documented \[[@B1-marinedrugs-18-00367]\]. They live in complex natural habitats, making them able to adapt rapidly in different extreme conditions such as variable salinity, temperature, nutrients and UV--irradiation. Therefore, they can produce a great variety of fascinating metabolites, with novel structures that possess biological activities which are not found in other organisms \[[@B2-marinedrugs-18-00367]\]. Microalgae produce some useful bio-products including β-carotene, astaxanthin, fucoxanthin, docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), bioactive and functional pigments, natural dyes, polysaccharides, amino acids, vitamins, antioxidants, and many more \[[@B3-marinedrugs-18-00367]\]. Algal research started in the 1950s, starting with studies on *Chlorella* and *Spirulina* species. *Chlorella* has been considered as an alternative in phytoremediation and potential source of renewable energy such as biodiesel due to its high lipid content \[[@B4-marinedrugs-18-00367]\]. Biodiesel production is primarily based on grease raw materials, such as palm oil, canola oil, animal tallow, and soybean oil \[[@B5-marinedrugs-18-00367]\]. However, the prices of these commodities are regulated by international laws which consequently affect biodiesel price, and about 80% of biodiesel costs vary with the price of grease raw materials \[[@B6-marinedrugs-18-00367]\], suggesting that new grease sources are needed in order to reduce the biodiesel price. As a result, there is growing interest in using microalgae for biodiesel production, especially because some produce about 150 times more oil per hectare than soybean \[[@B7-marinedrugs-18-00367]\]. Hence, the use of microalgae to produce biofuels has emerged as a promising alternative to the utilization of fossil fuels.

Single cell protein sources like microalgae have recently gained attention as protein sources for fish feed. In digestion trials with fish, microalgae are mostly fed in their natural form, grown without varying culture conditions or undergoing extraction \[[@B8-marinedrugs-18-00367]\]. Thus, microalgae are applied industrially in aquaculture hatcheries \[[@B9-marinedrugs-18-00367]\]. Normally fishes feed on microalgae as a natural source of nutrition. The microalgae can be safely used as a growth and immune stimulant because of their contents of essential amino acids, minerals, vitamins, chlorophylls, and some substances that have antioxidant capacities \[[@B10-marinedrugs-18-00367]\] like carotenoids and without worrying toxicity. Some microalgae are used mainly as healthy nutrition source in aquaculture in which they play important roles in the development of farming aquatic animals for healthy and profitable aquaculture practices \[[@B11-marinedrugs-18-00367],[@B12-marinedrugs-18-00367]\].

Currently, most diseases of cultured fish are treatable with drugs \[[@B13-marinedrugs-18-00367]\]. However, the drugs used are usually expensive and are more effective in the initial therapy. Furthermore, their application is not entirely safe as they may result in several problems such as development of resistance, accumulation of hazardous residues in the fishes \[[@B14-marinedrugs-18-00367]\] and can also lead to water contamination \[[@B15-marinedrugs-18-00367]\]. In this regard, supplementing fish diet with microalgae as a way to enhance fish immunity and resistance to diseases has gained more attention since microalgae do not pose the problems associated with drugs usage in fish treatment \[[@B16-marinedrugs-18-00367]\]. Algal biomass also contains other valuable components, such as pigments, omega-3 fatty acids, minerals and vitamins, which further increase the nutritional value of algae-based feed \[[@B17-marinedrugs-18-00367]\]. Previous studies have shown that adding microalgae to animal feed resulted in enhancements in growth, physiological activity, feed utilization efficiency \[[@B18-marinedrugs-18-00367]\], stress response, starvation tolerance, disease resistance and carcass quality of the cultured fish \[[@B19-marinedrugs-18-00367]\]. These enhancements are very likely due to the diversity of metabolites present in the microalgae.

*Chlorella vulgaris* is a green-colored, single-celled, and spherical freshwater microalgae belonging to the family Chlorellaceae of the division Chlorophyta. It is highly valued as a food supplement for both humans and animals due to its high medicinal value derived from its carotenoid, chlorophyll and protein contents \[[@B20-marinedrugs-18-00367]\]. It was reported that the incorporation of *C. vulgaris* in fish diets increased prophenoloxidase activity, total hemocyte, and resistance against *Macrobrachium rosenbergii* post larvae and *Aeromonas hydrophila* infections \[[@B21-marinedrugs-18-00367]\]. In addition, increased growth performance and total fish protein were both observed by using fish feed supplemented with *Chlorella* \[[@B21-marinedrugs-18-00367]\]. Past research also reported that *C. vulgaris* is a potential source of renewable energy due to its high lipid content. However, the total lipid content is dependent on culture conditions \[[@B22-marinedrugs-18-00367]\]. In addition, studies using FTIR indicated that polyol and amide constituents in *C. vulgaris* played critical role in synthesizing palladium nanoparticles by reducing the metal ions in an eco-friendly and non-toxic process \[[@B23-marinedrugs-18-00367]\]. Moreover, the proven tolerance limits of *C. vulgaris* against various heavy metals and metalloids, detoxifying water supply contaminated with As^+3^ \[[@B24-marinedrugs-18-00367]\], are significant advantages of using *C. vulgaris* over other microalgal strains.

Previous studies on *C. vulgaris* have reported an abundance of metabolites, including lipids, fatty acids, amino acids, simple sugars, and few carotenoids. However, there is limited mass spectroscopic data on most of the metabolites of the microalgae species in general \[[@B25-marinedrugs-18-00367]\]. Various studies were conducted on *C. vulgaris* and other microalgae strains using GC-MS spectrometry and UV-Vis spectroscopy, while very few involved LC-MS spectrometry. However, all these studies were focused on a specific class of metabolites (usually carotenoids or lipids), obtained as a result of optimizing growth medium formulation or *via* mutagenesis, without comprehensively profiling the metabolites that occur as a result of normal media formulation. Usually, normal media formulations like the bold Basal's media (BBM) (chemical composition) imitate the favorable natural conditions in which microalgae grow via metamorphosis. In addition, most of the researches also reported the unavoidable depletion of other metabolites in the course of enhancing the routes for the optimal production of the targeted metabolites of their research objective(s). For instance, *C. vulgaris* mutant strain was reported to have displayed superior lipid productivity with a minor PUFA level \[[@B26-marinedrugs-18-00367]\]. This is the same with total protein content of the wild species which solely depends on culturing conditions \[[@B27-marinedrugs-18-00367]\]. Under NO~3~ deficit, the production of photosynthetic pigments is drastically reduced with a huge decline of antioxidant activities particularly in *C. vulgaris* \[[@B28-marinedrugs-18-00367]\]. On the other hand, replete NO~3~ led to chlorophyll pigments and amino acid accumulation, while NO~3~ limitation produced a very low amino acid content but was very effective at increasing the generation of neutral lipid content \[[@B29-marinedrugs-18-00367],[@B30-marinedrugs-18-00367]\]. Furthermore, most of the identification carried out on the carotenoids and chlorophylls was conducted on dietary supplements containing *C. vulgaris*. However, there is no information available regarding the comprehensive metabolite profile of *C. vulgaris* cultured under normal growing conditions and formulation which is ideal for incorporation into diets. It is important to note that the metabolite composition of a microalgae may contribute in one way or another to its biological effect \[[@B31-marinedrugs-18-00367]\]. Thus, having an appreciably good knowledge of the diversity in metabolite composition is a prerequisite to understanding their correlation to the nutritional and pharmacological effects of the microalgae. Therefore, it is equally important to comprehensively profile microalgae grown under normal conditions and formulations in order to gain a better insight into the *C. vulgaris* metabolome, which is the aim of the present study.

2. Results and Discussion {#sec2-marinedrugs-18-00367}
=========================

2.1. Identification of Fatty Acids in Chlorella vulgaris {#sec2dot1-marinedrugs-18-00367}
--------------------------------------------------------

Extracted fatty acids from *C. vulgaris* were derivatized to fatty acid methyl esters (FAMEs) *via* reaction with acetyl chloride \[[@B32-marinedrugs-18-00367]\] and subjected to GC-MS analysis ([Figure 1](#marinedrugs-18-00367-f001){ref-type="fig"}A). From the *C. vulgaris*, nine saturated fatty acids ranging from C~14~ to C~22~ were detected, accounting for a percentage of 27.8% of the total fatty acids ([Figure 1](#marinedrugs-18-00367-f001){ref-type="fig"}B), while the unsaturated fatty acids accounted for 71.2% of the total fatty acids. The compositional ratio of fatty acids was calculated from peak areas which were integrated in total ion chromatogram as shown in [Figure 1](#marinedrugs-18-00367-f001){ref-type="fig"}.

The fatty acid profile of *C. vulgaris* is shown to be rich in omega-6, -7, -9, and -13 with omega-6 being the major fatty acid, representing more than sixty percent (\>60%) of the total fatty acids ([Figure 1](#marinedrugs-18-00367-f001){ref-type="fig"}D). This is a clear indication that this *Chlorella* species could serve as a good source of nutrition when incorporated in diets. The profile also showed that the fatty acid composition is mostly made up of C~16~-C~18~ (\>92%) fatty acid ([Figure 1](#marinedrugs-18-00367-f001){ref-type="fig"}C,D) which further supports *C. vulgaris* as a potential candidate for biodiesel production. These results are in agreement with the recently published work of Fernández-Linares et al. \[[@B33-marinedrugs-18-00367]\].

2.2. Metabolite Profiling of Chlorella vulgaris Ethanolic Extract {#sec2dot2-marinedrugs-18-00367}
-----------------------------------------------------------------

The ethanolic extract of *C. vulgaris* was analyzed by LC-MS/MS. The total scan PDA chromatogram and the total ion chromatogram of the extract are shown in [Figure 2](#marinedrugs-18-00367-f002){ref-type="fig"}A,B, respectively. The observed peaks indicating the different metabolites present in the sample were labeled with numbers. A general idea of the compound classes contained in the extract was first obtained from the UV absorptions of compound peaks observed in the total scan PDA chromatograms ([Figure 2](#marinedrugs-18-00367-f002){ref-type="fig"}A). Most of the UV-absorbing compounds detected by the photodiode array (PDA) detector showed maximum absorptions in the range of 200--300 nm. Nevertheless, carotenoids and chlorophyll pigments show characteristic absorption range of 200--400 nm and above, as a fingerprint that supports their identification. The identities of the metabolites were then further elucidated based on their molecular masses and mass fragmentation patterns ([Supplementary Figures S1--S5](#app1-marinedrugs-18-00367){ref-type="app"}). In some instances where the identity of a peak was masked by overlaps with other peaks of similar retention times, the extracted ion chromatogram (EIC) was obtained for metabolite identification, as in the case of astaxanthin ([supplementary materials Figure S6](#app1-marinedrugs-18-00367){ref-type="app"}). Although the LC-MS analysis was run in switching mode, almost all the compounds in the sample were better ionized in the positive mode. Therefore, identification of the compounds was conducted based on their full MS and MS/MS spectra obtained in positive ion mode.

### 2.2.1. Identification of Carotenoids {#sec2dot2dot1-marinedrugs-18-00367}

The carotenoids were easily recognizable based on their typical **λ*~max~*** values of 410, 430, 440 and 460 nm \[[@B33-marinedrugs-18-00367],[@B34-marinedrugs-18-00367],[@B35-marinedrugs-18-00367],[@B36-marinedrugs-18-00367],[@B37-marinedrugs-18-00367],[@B38-marinedrugs-18-00367],[@B39-marinedrugs-18-00367]\], as shown in [Table 2](#marinedrugs-18-00367-t002){ref-type="table"}. The mass fragmentation pathway for carotenoid peaks was very useful in assigning the mass fragments and greatly aided their identification.

Peak 6 showed characteristics which were consistent with that of vulgaxanthin I, with a parent ion at *m/z* 340 \[M + H\]^+^ (observed = *m/z* 340.2592 and exact = *m/z* 340.1139, error *m/z* 0.1453). The peak occurred at t~R~ 3.98 giving MS/MS fragment ions at *m/z* 322 (a loss of 18 amu due to the elimination of water from the protonated parent ion), *m/z* 209 (product of α-cleavage of the pi-bond dissociated parent ion that undergoes electron loss), and *m/z* 84 (α-cleavage at the amide terminal of the molecule). A possible fragmentation pathway for vulgaxanthin I is as shown in [Figure 3](#marinedrugs-18-00367-f003){ref-type="fig"}. The proposed fragment ions with *m/z* 339 and *m/z* 129, precursors to the fragment ions at *m/z* 209 and *m/z* 84, respectively, however were not detected by the MS detector. This could happen as a result of its rapid dissociation due to instability of the ions. Vulgaxanthin I has been previously identified in the higher plant *Berberis vulgaris* \[[@B40-marinedrugs-18-00367]\]. Although it has been reported before in brown algae *Chlorococcum humicola* \[[@B41-marinedrugs-18-00367]\], this is the first report of its occurrence in *C. vulgaris.*

Peaks 16 and 17 with t~R~ 14.35 and 14.52 were attributed to neoxanthin and violaxanthin, respectively. Both peaks showed similar parent ions at *m/z* 601.4 \[M + H\]^+^ and characteristic MS/MS fragment ions at *m/z* 583.4 \[M + H − 18\]^+^ due to loss of water molecule from the protonated parent ions. Both peaks also gave fragment ions at *m/z* 491.4 \[M + H − 92 − 18\]^+^, produced from a loss of C~7~H~8~ (92 amu: probably toluene) fragment along with one water molecule, and *m/z* 221.2 produced as a result of α-cleavage at one end of the molecules which occurred after a radical side rearrangement that precede the pi-bond dissociation of the parent ion ([Figure 4](#marinedrugs-18-00367-f004){ref-type="fig"}). Two additional MS/MS fragments were identified with violaxanthin at very low intensities, where the fragment *m/z* 565.4 \[M + H − 18 − 18\]^+^ corresponding to the loss of two successive water molecules and *m/z* 509.4 \[M + H − 92\]^+^, which is unique to violaxanthin \[[@B41-marinedrugs-18-00367]\], corresponds to the loss of a lone C~7~H~8~ fragment. These two peaks share the same parent ion and some MS/MS product ions, the differences in some of their fragmentation pattern suggest that they are isomers. These fragmentation results agree with previously published results \[[@B42-marinedrugs-18-00367]\]. Fragmentation pathways proposed for neoxanthin and violaxanthin are provided in [Supplementary Figures S1 and S2](#app1-marinedrugs-18-00367){ref-type="app"}, respectively.

Peak 18 with t~R~ 14.55--14.60 was attributed to antheraxanthin. This peak showed a parent ion at *m/z* 585 \[M + H\]^+^ and characteristic MS/MS fragments at *m/z* 567.4 \[M + H − 18\]^+^ due to loss of 18 amu corresponding to loss of water molecule, 475.4 \[M + H − 92 − 18\]^+^ corresponding to loss of C~7~H~8~ fragment along with a water molecule. The fragment *m/z* 221.1, was also produced with 100% intensity as expected \[[@B42-marinedrugs-18-00367]\]. Peak 20 at t~R~ 15.35--15.36, having a parent ion *m/z* 569.4 \[M + H\]^+^, exhibited two fragment ions with *m/z* 551.4 \[M + H − 18\]^+^ which occurred as a result of loss of one water molecule, and *m/z* 533.4 \[M + H − 18 − 18\]^+^ due to loss of two water molecules. This is characteristic of lutein and the absence of the fragment *m/z* 495, which would have resulted in further loss of 56 amu from the first fragment, suggested that the lutein identified in this sample is the isomer 15-*cis*-lutein \[[@B33-marinedrugs-18-00367]\]. Lutein fragmentation pathway was presented in [Supplementary Figure S3](#app1-marinedrugs-18-00367){ref-type="app"}. Peak 29 at t~R~ 23.15--23.16 with a parent ion *m/z* 536.4 \[M + H\]^+^ and MS/MS fragment ions at *m/z* 444.4 \[M + H − 92\]^+^ and *m/z* 321.3 was attributed to β-carotene \[[@B42-marinedrugs-18-00367]\]. The fragmentation pathway for β-carotene is provided in [Supplementary Figure S4](#app1-marinedrugs-18-00367){ref-type="app"}.

Peak number 26, which was not clearly seen in [Figure 2](#marinedrugs-18-00367-f002){ref-type="fig"}B due to overlap, was identified from its EIC ([Supplementary Figure S6](#app1-marinedrugs-18-00367){ref-type="app"}**)** which showed a peak at t~R~ 19.21 with parent ion at *m/z* 596.6 \[M + H\]^+^. The parent ion further dissociated to give fragment ions at *m/z* 578.6 \[M + H − 18\]^+^ and 560.6 \[M + H − 18 − 18\]^+^ corresponding to losses of 18 amu and 36 amu for successive loss of one and two water molecules, respectively. Based on this information, peak 26 was identified as astaxanthin \[[@B33-marinedrugs-18-00367]\]. The fragmentation pathway for astaxanthin is shown in [Supplementary Figure S5](#app1-marinedrugs-18-00367){ref-type="app"}. The carotenoids detected in this work agree with recently published data \[[@B43-marinedrugs-18-00367],[@B44-marinedrugs-18-00367]\].

### 2.2.2. Identification of Chlorophyll Pigments {#sec2dot2dot2-marinedrugs-18-00367}

The chlorophylls are macromolecules with highly conjugated systems that do not always give MS/MS fragments data under the range of collision energy usually set for other molecules of lower masses. Hence their identification is best conducted with the help of their UV spectrum. Chlorophyll pigments (peaks 19 and 27--31) showed characteristic λ***~max~*** values in the range between 210 and 530 nm \[[@B35-marinedrugs-18-00367]\], as tabulated in [Table 3](#marinedrugs-18-00367-t003){ref-type="table"}, which also lists their respective parent ion masses. Compound identification made use of the mass fragmentation data provided in [supplementary material](#app1-marinedrugs-18-00367){ref-type="app"} ([Supplementary Figure S7](#app1-marinedrugs-18-00367){ref-type="app"}).

Peak 19, the most intense peak in the UV PDA, at t~R~ 14.68 with characteristic *λ~max~* absorptions of 268, 474 and 536 nm was identified as pheophorbide-a based on the parent ion at *m/z* 593 \[M + H\]^+^ in which correspond to its MS base peak at t~R~ 14.74. Peak 27 is pheophytin-b with parent ion at *m/z* 885 \[M + H\]^+^ at MS t~R~ 21.13 (peak **27**) gives a UV peak at t~R~ 21.08 with absorption band of *λ~max~* 222, 436, 528 nm. Pheophorbide-b with parent ion *m/z* \[M + H\]^+^ 607 was assigned to peak 28. This peak was found under the MS t~R~ 21.25 which corresponds to the UV PDA observed peak at t~R~ 20.90 that show an absorption band of *λ~max~* 222, 436 and 528 nm. Pheophytin-a having an MS parent ion *m/z* 871 \[M + H\]^+^ at t~R~ 24.30 (peak 30**)** also shows a UV peak at t~R~ 24.28 with absorption band of *λ~max~* 408, 536 nm, corresponds with previously reported data \[[@B34-marinedrugs-18-00367]\]. The peak with t~R~ 28.70 (peak 31**)** gives a mass peak of *m/z* 894 \[M + H\]^+^corresponding to a UV peak at t~R~ 28.66 having an absorption of *λ~max~* 410, 538 nm, is attributed to chlorophyll a. The detected chlorophylic pigments agree with recently published data \[[@B44-marinedrugs-18-00367],[@B45-marinedrugs-18-00367],[@B46-marinedrugs-18-00367]\].

### 2.2.3. Identification of Amino Acids, Fatty Acids, Lipids and Fatty Acyls {#sec2dot2dot3-marinedrugs-18-00367}

[Table 4](#marinedrugs-18-00367-t004){ref-type="table"} shows peaks 2, 3, 5, 7 and 9 for the amino acids present in *C. vulgaris*. At t~R~ 1.44 leucine (peak 2) was observed to fragment into *m/z* 115, 86, 72 and 57. The characteristic MS/MS fragmentation pattern for peak 3 at t~R~ 2.29 with fragment ions *m/z* 165, 120, 103, 93, 91, 79, was attributable to phenylalanine. Peak 5 at t~R~ 2.72 with *m/z* 205 and 100% relative abundance was identified as tryptophan based on the fragment ions *m/z* 146, 144, 143, 142, 132, 118, 91, and 74. Lysophosphatidylethanolamine (Lyso-PE) was assigned to peak 7 at t~R~ 5.44 with fragment ion ions *m/z* 548, 452, 322, 209, 157, 114, 97, and 57. Disopyramide was the peak at t~R~ 6.30 with fragment ions *m/z* 322, 306, 212, 196, 114, and 74. [Table 4](#marinedrugs-18-00367-t004){ref-type="table"} also shows the identified fatty acids, fatty acyls and lipids.

The identified amino acids, fatty acids and some of the lipids via LCMS agree with recently published results \[[@B47-marinedrugs-18-00367],[@B48-marinedrugs-18-00367]\].

### 2.2.4. Identification of Vitamins {#sec2dot2dot4-marinedrugs-18-00367}

Vitamin B-3 (nicotinic acid) was identified by fragment ions *m/z* 123, 80, 78, 53, and 45 which occurred due to peak 1 at t~R~ 1.33. Peak 4 at t~R~ 2.54 with characteristic fragmentation pattern *m/z* 142, 116, 103, 90, 87, 86, 73, 72, 70, 57, and 55 is attributed to vitamin B-5 (pantothenic acid).

### 2.2.5. Identification of Other Compounds {#sec2dot2dot5-marinedrugs-18-00367}

The identification of simple sugars in the complex crude ethanol fraction of *C. vulgaris* was not very successful and hence very few were identified ([Table 6](#marinedrugs-18-00367-t006){ref-type="table"}). This may be attributed to many factors including the probability of many adduct formations which were not completely identified due to the large error values calculated in relation to the literature. (*R*)-cryptone, input *m/z* 139.1228 and exact *m/z* 139.1117 therefore error *m/z* 0.0111, is known to be found in the higher plant *Eucalyptus bosistoana* \[[@B49-marinedrugs-18-00367]\] and has never been reported before as a component metabolite of *C. vulgaris* in the literature. Hence further research is ongoing to establish more facts regarding its identification in *C. vulgaris.* The proposed mass fragment ions resulting from fragmentation of *R*-cryptone are shown in [Figure 5](#marinedrugs-18-00367-f005){ref-type="fig"}. The detected simple sugars agree with previously published results \[[@B46-marinedrugs-18-00367]\].

### 2.2.6. Identification of Lipids via Molecular Networking {#sec2dot2dot6-marinedrugs-18-00367}

Molecular networking (MN) assists in data mining *via* clustering of the MS/MS spectra based on fragmentation cosine similarities \[[@B50-marinedrugs-18-00367],[@B51-marinedrugs-18-00367]\]. The molecular network of the ethanol extract was generated in order to analyze the lipid content of *C. vulgaris* more comprehensively, to enrich the information obtained from the fatty acid analysis *via* GC-MS. Therefore, the typical nature of the lipid content can be fully viewed *via* a putative annotation of the different lipids that make up the important property of *C. vulgaris* as a potential candidate for nutrition and biodiesel production using MN. [Figure 6](#marinedrugs-18-00367-f006){ref-type="fig"} shows the generated MN with the different clusters, each cluster shared some distinct fragments and fragmentation pattern.

The putative annotation was conducted with reference to different mass spectroscopic data bases. Three major and distinct clusters were observed in the network comprising diacylglycerophosphoserines, diacylglycerophosphocholines, and glycosphingolipids clusters. Another cluster comprising several separate sub-clusters of monoacylglycerophosphoethanolamines was also detected. Identification of the metabolites was performed based on the systematic study of the fragmentation pathways and patterns observed from the resulting network. The mass spectrometry-based MN allowed the identification and putative annotation of 48 lipids in the major clusters as shown in [Table 7](#marinedrugs-18-00367-t007){ref-type="table"}. The MN was capable not only to dereplicate known lipids, but also pointed out related derivatives, described for the first time in *C. vulgaris*. The resulting annotation from MN conforms with those obtained from GCMS fatty acid analysis in terms of the number and degree of unsaturation; most of the lipids identified from the MN contain the substituent fatty acid carbon ring ranging from C~16~-C~18~ which mostly belong to omega 6 fatty acids containing 2--3 degrees of alkene unsaturation.

Visual inspection of the *C. vulgaris* MN showed that glycosphingolipids clustered in agreement with their substituent's similarities, i.e., grouped according to the type and size of the attached fatty acids. All the glycosphingolipids identified are mainly disubstituted lipids and mostly contain dialkene with few saturated, mono- and tri-alkene fatty acid substituents. Some phosphoethanolamines which were totally absent in their class cluster, were also seen in this cluster sharing some common fragments with glycosphingolipids. Therefore, the typical nature of the lipid content can be fully viewed via a putative annotation of the different lipids that make up the important property of *C. vulgaris* as a potential candidate for nutrition and biodiesel production using MN.

Some of the identified lipids agree with previously published results \[[@B52-marinedrugs-18-00367],[@B53-marinedrugs-18-00367]\].

The fragmentation pattern in phosphoserine cluster ([Figure 7](#marinedrugs-18-00367-f007){ref-type="fig"}) is observed by the π-bond dissociation of one of the alkene bonds of the corresponding fatty acid to yield a free radical ion that eventually leads to the elimination of C~2~H~5~ or C~3~H~7~ via б-bond dissociation. These fragments correspond to a loss of 29 and 43 amu, respectively. The fragment *m/z* 837 was a result of radical-site rearrangement that led to the elimination of two subsequent H~2~O molecules via α-bond cleavage corresponding to a loss of 18 amu. In addition, fragment *m/z* 593 mostly occurred as a result of the complete elimination of one of the fatty acid substituents as a result of γ-charge-site rearrangement. Fragments *m/z* 178 and *m/z* 113 were due to б-bond dissociation eliminating two alkene bonds involving 13 C-atoms and or without the alkene bonds involving only 8 C-atoms respectively as seen in [Figure 8](#marinedrugs-18-00367-f008){ref-type="fig"}.

The fragmentation pattern in diacylglycerophosphocholines ([Figure 9](#marinedrugs-18-00367-f009){ref-type="fig"}) is slightly different from the other classes because most of the commonly shared fragments among the lipids of this group contain the phospho-terminal of the lipid molecule. For instance, fragment *m/z* 189, which was a result of charge-remote rearrangement, contained both the phospho-terminal as well as two hydroxyl groups (OH). Other fragments *m/z* 137, 125, 99, and 81 contain only the phospho-terminal in different ionic forms which are also products of charge-remote rearrangements, and in few instances, from inductive cleavages, as shown in [Figure 10](#marinedrugs-18-00367-f010){ref-type="fig"}.

The largest cluster of the MN, glycosphingolipids ([Figure 11](#marinedrugs-18-00367-f011){ref-type="fig"}), are mainly characterized by the presence of one or two tetrahydropyran rings within the fragments and the presence of mono-alkene substituted fatty acids, as shown in [Figure 12](#marinedrugs-18-00367-f012){ref-type="fig"}.

3. Materials and Methods {#sec3-marinedrugs-18-00367}
========================

3.1. Fresh Water Microalgae Culture {#sec3dot1-marinedrugs-18-00367}
-----------------------------------

*Chlorella vulgaris* was obtained from the Aquatic Laboratory Faculty of Veterinary Medicine, Universiti Putra Malaysia and prepared by raising 200 L of cultured media from 40 milliliters of starter-culture using Bold Basal's media (BBM). The whole process was conducted in duplicate (100 L each). The upscaling of culture was done *via* the addition of ten liters of culturing media in three days interval after the growth is checked using hemacytometer under a 400× microscope. The parameter for the algal culture was adopted from the original BBM media with slight modification in temperature which we could not maintain at 28 °C (changes in the range of 25--30 °C). The microalgae biomass production was cultivated in fresh water containing the prepared BBM media having various concentrations of different acids and trace elements autoclaved solutions. The growth medium was adjusted and monitored at pH 7.5. The wet crude product was harvested via centrifugation by employing high-speed Sorvall Evolution RC centrifuge (Thermo Electron Corporation, Asheville, NC, USA) at 12,000 rpm at 25 °C, kept at −80°C for five days, and lyophilized using a freeze drier \[[@B48-marinedrugs-18-00367]\]. Solvent extraction was carried out with ethanol and for LC-MS/MS analysis.

3.2. Solvents and Chemicals {#sec3dot2-marinedrugs-18-00367}
---------------------------

Analytical grade methanol, ethanol, ethyl acetate, chloroform and hexane were purchased from Merck Millipore (Darmstadt, Germany).

3.3. Microalgae Solvent Extraction Procedure {#sec3dot3-marinedrugs-18-00367}
--------------------------------------------

Lyophilized microalgae biomass (100 mg) was dissolved in 50 mL ethanol and vortexed for 5 min. The solution was then extracted *via* sonication for 30 min using ultrasonic water bath (SK8210HP Shanghai KUDOS Ultrasonic Instrument Co. Ltd., Shanghai, China) at room temperature. The solvent extract was then filtered through Whatman No. 1 filter paper and the procedure is repeated with another 50 mL of ethanol for a second and third round of extraction. The filtered extracts were pooled and evaporated to dryness using a rotary evaporator (Heidolph Instruments GmbH amd Co.KG, Schwabach, Germany) at 30 °C, and stored at −20 °C until further analysis. The ethanol fraction was then used for LC-MS analysis.

3.4. Extraction of Fatty Acids for GC-MS Analysis {#sec3dot4-marinedrugs-18-00367}
-------------------------------------------------

Fatty acids in the crude sample of *C. vulgaris* (\~3 mg) were extracted using chloroform and methanol (1:2 v/v) by an ultrasonic device for 10 min. To separate the residue, the mixture was separated by centrifugation at 3000 rpm for 10 min, and the liquid phase was transferred into a glass tube. These extraction steps were repeated three times to obtain maximum extract. After the extraction, several ml of Milli Q water was added, the glass tube was shaken using vortex. Then, to separate impurities (which were dissolved in the water) and the organic solvent phase containing fatty acids, the glass tube was centrifuged at 3000 rpm for 10 min. The water was removed, and the organic solvent phase was dried once. Derivatization into FAMEs were performed with acetyl chloride and methanol (5:100 v/v) \[[@B32-marinedrugs-18-00367]\]. A 10ml acetyl chloride and methanol was added into the dried glass tube, and the derivatization was achieved by reacting under heat at 100 °C for 60 min using a heat block. After cooling at room temperate, the glass tube was added 2 ml of hexane and shake well, and then an aliquot of the upper phase was transferred to a new glass vial. This extraction step was repeated two more times. The final removal of hexane was performed on a 40 °C hot plate with nitrogen stream. Then, the sample was resolved with an accurate amount of hexane (300 µL). Finally, 1 μL of the sample was injected into a GC--MS for fatty acid analysis. Using this method, non-esterified fatty acids were obtained \[[@B49-marinedrugs-18-00367]\]. The identification of FAMEs was assisted by National Institute of Standards and Technology Library (NIST 17 version 2.3) and was confirmed manually. The mono-unsaturated fatty acids were manually detected by the presence of intense peaks of *m/z* 55 and *m/z* 69 along with the molecular weight peak. Meanwhile, the di-unsaturated fatty acids were detected by the presence of *m/z* 55 and *m/z* 67 intense peaks and *m/z* 74 and *m/z* 87 intense peaks were features of saturated fatty acids.

3.5. Sample Preparation for UHPLC-MS/MS Analysis {#sec3dot5-marinedrugs-18-00367}
------------------------------------------------

The ethanol extract (2 mg) was dissolved in LCMS-grade methanol (1 mL). Dissolved extract was vortexed for 10 min, centrifuged for 10 min and filtered through a nylon filter (0.22 µm) into a glass vial for LC-MS/MS analysis \[[@B50-marinedrugs-18-00367]\].

3.6. GC-MS Analysis {#sec3dot6-marinedrugs-18-00367}
-------------------

The extracted fatty acids were analyzed using a gas chromatography (GC, HP 6890)-mass spectrometry (MS, HP 5973) (Hewlett Packard, Palo Alto, CA, USA). The GC column was set ZB-WAX column, 30 m (length) × 0.25 mm (I.D) × 0.25 μm film thickness. Helium was used as the carrier gas with a flow rate of 1.0 mL/min. The injector was set at 220 °C in split mode. The temperature gradient of the GC oven started with a 70 °C initial temperature, a linear increase to 170 °C at 11 °C /min, a slower linear increase to 175 °C at 0.8 °C /min, followed by an increase to reach 220 °C at 20 °C/min and a final 2.5 min hold. The total run time was 60 min. The MS quadrupole and MS ion source were programmed at 150 °C and 230 °C, respectively. MS data were obtained with scan mode scanning from 20 to 450 amu.

Analysis of MS data for the fatty acids was conducted using enhanced MSD ChemStation E.02.02.143 (Agilent Technologies, Inc. Santa Clara, CA, USA) fitted with NIST Library database (NIST 17 Version 2.3). The compositional rate in fatty acids was calculated from a comparison of each area in the fatty acids taken from the total ion chromatogram.

3.7. UHPLC-MS/MS Analysis {#sec3dot7-marinedrugs-18-00367}
-------------------------

The crude methanol extract was separated using a C18 Reversed-phase Hypersil GOLD aQ column (100 × 2.1 mm \~1.9 µm) (Thermo, Waltham, MA, USA) at 30 °C on Dionex Ultimate 3000 UHPLC with a diode-array DAD-3000 detector (Thermo Fisher Scientific, Waltham, MA, USA). Gradient elution was performed with LC-MS grade Solvent A (0.1% formic acid and 10 mMol ammonium formate in 500 mL methanol (70%) and acetonitrile (30%)) and Solvent B (0.1% formic acid and 10 mMol ammonium formate in 500 mL water) for the following gradient: 20% A in 5 min, and 20--80% A in the next 25 min at a flow rate of 0.2 mL/min. The concentration of sample extract was 1 mg/mL and the injection volume were set to 10 µL and the UV detector was set at 210, 310, 410 and 510 nm. The MS analysis was done on Q-Exactive Focus Orbitrap LC-MS/MS system. The eluent was monitored by ESI-MS under positive and negative switching mode and scanned from *m/z* 100 to 1500 amu. ESI was conducted using a spray voltage of 4.2 kV. High purity nitrogen gas was used as dry gas at a sheath gas flow rate of 40 (arbitrary units) and aux gas flow rate of 10 (arbitrary units). Capillary temperature was set at 350 °C while aux gas heater temperature was set at 10 °C. The MS data analysis was conducted using ThermoXcalibur 2.2 SP1.48 (Thermo Fisher Inc. Waltham, MA, USA) and literature data. Further, the confirmation of newly identified compounds was supported by its mass error that shows relatively low values indicating the high possibility of correct identification of the newly reported compounds.

The mass spectrometry molecular networks were created using the Global Natural Products Social Molecular Networking (GNPS) platform (<http://gnps.ucsd.edu>) \[[@B51-marinedrugs-18-00367]\]. The MS data were first converted into mzXML format using MSConvert \[[@B51-marinedrugs-18-00367]\]. Spectral information generated was uploaded on GNPS using FileZilla and was used to generate an MS/MS molecular network using the GNPS Data Analysis Workflow. The precursor ion mass tolerance was set to 0.02 Da and a fragment ion mass tolerance of 0.02 Da. The fragment ions below 10 counts were removed from the MS/MS spectra. The MN were generated using 6 minimum matched peaks and a cosine score of 0.7. The resulting data were downloaded and visualized using Cytoscape 3.7.1 software (Institute of Systems Biology Seattle, Washington D.C., USA) \[[@B50-marinedrugs-18-00367]\].

4. Conclusions {#sec4-marinedrugs-18-00367}
==============

MS-based metabolite profiling of crude sample of *C. vulgaris* microalgae grown in normal conditions, proved to be efficient in the determination of certain metabolites including carotenoids, amino acids, vitamins and other pigments such as the chlorophylls. The combination of methanol 70% and acetonitrile 30% as the organic solvent used proved to be efficient in determining these compounds. In total, 31 metabolites were successfully determined using LC-MS among which two of them, vulgaxanthin I and R-crypton, were never reported in *C. vulgaris* before. In addition, 48 lipids were putatively identified via MN. On the other hand, the fatty acid content was best determined using GC-MS via fatty acid analysis due to their volatility and ease of derivatization into FAME, and a total of 20 fatty acids were identified in the derivatized sample with higher percentage of unsaturation and omega-6 being the most dominant. Recent novel bioinformatics approaches such as the MN and in-silico fragmentation tools have emerged and provided a new perspective for early metabolite identification in natural products research. Thus, in this research, an efficient exploitation of datasets was employed for automated data treatment and access to dedicated fragmentation databases during MN. As a result, a larger profile of *C. vulgaris* was successfully established and many lipids were putatively identified which were not reported before.

The presence of carotenoids, chlorophylls and amino acids suggests that the candidate sample *C. vulgaris* is a good source of nutrition supported by the presence of omega-6, -7, -9, and -13 fatty acids. Also, the fatty acid profile suggests that *C. vulgaris* is a good candidate for biodiesel production. More studies need to be carried out in order to determine the correct proportion of nutrient composition in this promising microalga.
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![(**A**) Total ion chromatogram of extracted fatty acid methyl esters in *Chlorella vulgaris* obtained by GC−MS analysis (numbers correspond to peak numbers in [Table 1](#marinedrugs-18-00367-t001){ref-type="table"}) (**B**) The percentage composition of saturated and unsaturated fatty acid methyl esters (**C**) Percentage distribution of individual saturated fatty acids relative to the total saturated fatty acid content (**D**) Percentage distribution of individual unsaturated fatty acids relative to the total unsaturated fatty acid content.](marinedrugs-18-00367-g001){#marinedrugs-18-00367-f001}

![(**A**) Total scan PDA chromatogram and (**B**) total ion chromatogram (TIC) in positive ion mode of *Chlorella vulgaris*. The number above each peak represent peak numbers, corresponding to the peak numbers in [Table 2](#marinedrugs-18-00367-t002){ref-type="table"}, [Table 3](#marinedrugs-18-00367-t003){ref-type="table"}, [Table 4](#marinedrugs-18-00367-t004){ref-type="table"} and [Table 5](#marinedrugs-18-00367-t005){ref-type="table"}.](marinedrugs-18-00367-g002){#marinedrugs-18-00367-f002}

![Proposed fragmentation pathway for vulgaxanthin I.](marinedrugs-18-00367-g003){#marinedrugs-18-00367-f003}

![Proposed fragmentation pathways for neoxanthin and violaxanthin, producing *m/z* 221 fragment ions.](marinedrugs-18-00367-g004){#marinedrugs-18-00367-f004}

![Proposed mass fragments resulting from fragmentation of *R*-cryptone**.**](marinedrugs-18-00367-g005){#marinedrugs-18-00367-f005}

![Full molecular network of *Chlorella vulgaris* ethanol extract showing lipid clusters consisting of diacylglycerophosphoserines, diacylglycerophosphocholines, glycosphingolipids, several small clusters of monoacylglycerophosphoethanolamines (a,b,c,d) and an unidentified cluster. Structures shown are representative examples of the lipids in each cluster.](marinedrugs-18-00367-g006){#marinedrugs-18-00367-f006}

![Diacylglycerophosphoserine cluster with MS1 showing the nodes. Numbers correspond to lipid number as listed in [Table 7](#marinedrugs-18-00367-t007){ref-type="table"}.](marinedrugs-18-00367-g007){#marinedrugs-18-00367-f007}

![Diacylglycerophosphoserines cluster(1); some of the common fragments within the cluster.](marinedrugs-18-00367-g008){#marinedrugs-18-00367-f008}

![Diacylglycerophosphocholine cluster with MS1 showing the nodes. Numbers correspond to lipid number as listed in [Table 7](#marinedrugs-18-00367-t007){ref-type="table"}.](marinedrugs-18-00367-g009){#marinedrugs-18-00367-f009}

![Some common fragments within the diacylglycerophosphocholine cluster based on MS2.](marinedrugs-18-00367-g010){#marinedrugs-18-00367-f010}

![Glycosphingolipid cluster with MS1 showing the nodes. Numbers correspond to lipid number as listed in [Table 7](#marinedrugs-18-00367-t007){ref-type="table"}.](marinedrugs-18-00367-g011){#marinedrugs-18-00367-f011}

![Some common fragments within the glycosphingolipid cluster based on MS1 and MS2.](marinedrugs-18-00367-g012){#marinedrugs-18-00367-f012}
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###### 

Fatty acid composition of *Chlorella vulgaris.* The table shows the peak numbers, the corresponding systematic and trivial names of the fatty acid, designation and percentage composition.

  Peak   Systematic Name                   Trivial Name         Designation         Composition (%)
  ------ --------------------------------- -------------------- ------------------- -----------------
  1      Tetradecanoic acid                Myristic acid        C~14~               1.0
  2      Pentadecanoic acid                \-                   C~15~               0.4
  3      Hexadecanoic acid                 Palmitic acid        C~16~               16.4
  4      9-Hexadecenoic acid               Palmitoleic acid     C~16:1\ \[n-7\]~    1.5
  5      Heptadecanoic acid                Margaric acid        C~17~               1.2
  6      7,10-Hexadecadienoic acid         \-                   C~16:2\ \[n-6\]~    20.4
  7      Octadecanoic acid                 Stearic acid         C~18~               2.8
  8      5-Octadecenoic acid               \-                   C~18:1\ \[n-13\]~   0.3
  9      9-Octadecenoic acid               Oleic acid           C~18:1\ \[n-9\]~    4.2
  10     11-Octadecenoic acid              \-                   C~18:1\ \[n-7\]~    2.0
  11     9,12-Octadecadienoic acid         Linoleic acid        C~18:2\ \[n-6\]~    35.1
  12     Nonadecanoic acid                 Nonadecylic acid     C~19~               0.2
  13     9,12,15-Octadecatrienoic acid     Linolenic acid       C~18:3\ \[n-6\]~    5.2
  14     Eicosanoic acid                   Arachidic acid       C~20~               5.7
  15     9-Eicosenoic acid                 \-                   C~20:1\ \[n-9\]~    0.4
  16     Eicosadienoic acid                \-                   C~20:2~             1.3
  17     11,14,17-Eicosatrienoic acid      Homolinolenic acid   C~20:3\ \[n-6\]~    0.4
  18     Heneicosanoic acid                Heneicosylic acid    C~21~               0.2
  19     5,8,11,14-Eicosatetraenoic acid   Arachidonic acid     C~20:4\ \[n-6\]~    0.6
  20     Docosanoic acid                   Behenic acid         C~22~               0.9

marinedrugs-18-00367-t002_Table 2

###### 

Carotenoids identified in *Chlorella vulgaris*. The underlined fragment ion is unique to the corresponding compound**.** The table shows peak number, name of the carotenoid, retention time in minutes (t~R~), characteristic absorption frequencies in nanometers (*λ~max~*), parent ion \[M + H\]^+^ mass per charge ratio, MS/MS mass per charge ratio of fragment ions, and references.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Peak   Carotenoid       t~R~ (min)     λ*~max~* (nm)   \[M + H\]^+^ (*m/z*)   MS/MS (*m/z*)                       References
  ------ ---------------- -------------- --------------- ---------------------- ----------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------
  6      Vulgaxanthin I   3.98           424, 476        340                    322 (M + H − 18)^+^ (20%)\          Not previously reported\
                                                                                209 (100%), 84 (3%)                 in *C. vulgaris*

  16     Neoxanthin       14.35          414, 436, 462   601.4                  583.4 (M + H − 18)^+^ (8%)\         \[[@B33-marinedrugs-18-00367],[@B34-marinedrugs-18-00367],[@B36-marinedrugs-18-00367]\]
                                                                                491.4 (M + H − 92 − 18)^+^ (10%)\   
                                                                                221.2 (100%)                        

  17     Violaxanthin     14.52          416, 442        601.4                  583.4 (M + H − 18)^+^ (6%)\         \[[@B33-marinedrugs-18-00367],[@B34-marinedrugs-18-00367],[@B36-marinedrugs-18-00367],[@B37-marinedrugs-18-00367],[@B38-marinedrugs-18-00367]\]
                                                                                565.4 (M + H − 18 − 18)^+^ (4%)\    
                                                                                509.4 (M + H − 92)^+^ (4%)\         
                                                                                491.4 (M + H − 92 − 18)^+^ (7%)\    
                                                                                221.2 (100%)                        

  18     Antheraxanthin   14.55--14.60   400, 424        585.4                  567.4 (M + H − 18)^+^ (35%)\        \[[@B35-marinedrugs-18-00367],[@B38-marinedrugs-18-00367]\]
                                                                                475.4 (M + H − 92 − 18)^+^ (10%)\   
                                                                                221.2 (100%)                        

  20     Lutein           15.35--15.36   414, 438, 464   569.4                  551.4 (M + H − 18)^+^ (25%)\        \[[@B32-marinedrugs-18-00367],[@B33-marinedrugs-18-00367],[@B34-marinedrugs-18-00367],[@B36-marinedrugs-18-00367]\]
                                                                                533.4 (M + H − 18 − 18)^+^ (5%)     

  26     Astaxanthin      19.21          372, 436        596.6                  578.6 (M + H − 18)^+^ (100%)\       \[[@B39-marinedrugs-18-00367]\]
                                                                                560.6 (M + H − 18 − 18)^+^ (10%)\   
                                                                                284.3 (50%)                         

  29     β-carotene       23.15--23.16   412, 440, 468   536.4                  444.4 (M + H − 92)^+^ (20%)\        \[[@B33-marinedrugs-18-00367],[@B34-marinedrugs-18-00367],[@B39-marinedrugs-18-00367]\]
                                                                                321.3 (18%)                         
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

marinedrugs-18-00367-t003_Table 3

###### 

Chlorophylic pigments identified in *Chlorella vulgaris**.*** The table shows peak number, the corresponding pigment name, retention time in minutes (t~R~), characteristic absorption frequencies in nanometers (*λ~max~*), parent ion \[M + H\]^+^ mass per charge ratio, and references.

  Peak   Pigment          t~R~ (min)   λ~max~ (nm)               \[M + H\]^+^ (*m/z*)   References
  ------ ---------------- ------------ ------------------------- ---------------------- ---------------------------------
  19     Pheophorbide-a   14.68        268, 474, 536             593                    \[[@B34-marinedrugs-18-00367]\]
  27     Pheophytin-b     21.08        222, 436, 528             885                    \[[@B34-marinedrugs-18-00367]\]
  28     Pheophorbide-b   21.37        202, 222, 372, 436, 528   607                    \[[@B34-marinedrugs-18-00367]\]
  30     Pheophytin-a     24.28        204, 408, 536             871                    \[[@B34-marinedrugs-18-00367]\]
  31     Chlorophyll-a    28.66        202, 410, 538             894                    \[[@B34-marinedrugs-18-00367]\]

marinedrugs-18-00367-t004_Table 4

###### 

Amino acids, fatty acids, lipids and fatty acyls composition of *Chlorella vulgaris*. Underlined *m/z* values indicate intense fragments**.** The table shows peak numbers, corresponding compound name, retention time in minutes (t~R~), parent ion \[M + H\]^+^ mass per charge ratio and MS/MS mass per charge ratio of fragment ions.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Peak   Amino Acid                                 t~R~ (min)   \[M + H\]^+^ (*m/z*)   MS/MS (*m/z)*
  ------ ------------------------------------------ ------------ ---------------------- ------------------------------------------------------------------------------------------------------------------------
  2      Leucine                                    1.44         132                    [115]{.ul}, [86]{.ul}, [72]{.ul}, [57]{.ul}

  3      Phenylalanine                              2.29         166                    165, [120]{.ul}, 103, 93, [91]{.ul}, [79]{.ul}

  5      Tryptophan                                 2.72         205                    [159]{.ul}, 146, 144, 143, 142, [132]{.ul}, [118]{.ul}, 91, [74]{.ul}

  7      Lysophosphatidylethanolamine \[Lyso-PE\]   5.44         566                    [548]{.ul}, [452]{.ul}, [322]{.ul}, [209]{.ul}, [157]{.ul}, 114, [97]{.ul}, 57

  9      Disopyramide                               6.30         340                    [322]{.ul}, 306, [212]{.ul}, [196]{.ul}, [114]{.ul}, 74

         **Fatty acids**                                                                

  13     Fatty acid                                 12.22        492                    474, 309, 258, [184,]{.ul} 141, 138, 124, 112, [104,]{.ul} 102, 86, 78, 70, [60]{.ul}

  21     Nonadecanoyloxyoctadeca-\                  15.98        575                    447, 263, 239, 221, 161, 137, [109,]{.ul} [95,]{.ul} [81,]{.ul} 71, [69,]{.ul} 57, 55
         trienoic acid                                                                  

  12     1-Acetoxy-2-hydroxy-16-\                   11.70        325                    233, 215, 175, 173, 145, 135, 121, 109, 95, [93,]{.ul} 91, [81,]{.ul} [67]{.ul}
         heptadecyn-4-one                                                               

  14     Hexadecatrienal                            12.51        235                    226, 211, 173, 153, 133, 119, 111, 109 [105,]{.ul} [95,]{.ul} [91,]{.ul} [81,]{.ul} [79,]{.ul} [67,]{.ul} [55]{.ul} 53

         **Lipids**                                                                     

  15     1-\[9*Z*,12*Z*-octadecadienoyl\]-sn-\      13.44        520                    502, 484, 342, 337, 260, [184,]{.ul} 125, 104, [86,]{.ul} 60
         glycero -3-phosphocholine                                                      

  22     1-hexadecanoyl-2-\[5*Z*,8*Z*,11*Z*,\       16.35        782                    782, 184, 124, [184]{.ul}, 86
         14*Z*-eicosatetraenoyl\]-sn-\                                                  
         glycero-3-phosphocholine                                                       

  23     1-tetradecanoyl-2-\[11*Z*,14*Z*-\          16.80        758                    553, 357, 199, [184,]{.ul} 124, [86]{.ul}
         eicosadienoyl\]-glycero-3-\                                                    
         phosphocholine                                                                 

  24     1-hexadecanoyl-2-\[11*Z*,14*Z*-\           17.74        786                    688, 552, 501, 474, 215, [184,]{.ul} 125, 104, 87, [86,]{.ul} 60
         eicosadienoyl\]-glycero-3-\                                                    
         phosphocholine                                                                 

  25     1-octadecanoyl-2-\[11*Z*,14*Z*-\           18.74        814                    673, 614, 513, 462, 338, [184,]{.ul} 130, 104, [86]{.ul}
         eicosadienoyl\]-sn-glycero-3-\                                                 
         phosphocholine                                                                 
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

marinedrugs-18-00367-t005_Table 5

###### 

Composition of vitamins in *Chlorella vulgaris*. Underlined *m/z* values indicate intense fragments**.** The table show peak numbers, corresponding vitamin name, retention time in minutes (t~R~), parent ion \[M + H\]^+^ mass per charge ratio and MS/MS mass per charge ratio of fragment ions.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Peak   Vitamin                t~R~ (min)   \[M + H\]^+^ (*m/z*)   MS/MS (*m/z)*
  ------ ---------------------- ------------ ---------------------- -------------------------------------------------------------------------------------------------------
  1      Vitamin B-3\           1.33         124                    [123]{.ul}, [80]{.ul}, 78, 53, [45]{.ul}
         \[nicotinic acid\]                                         

  4      Vitamin B-5\           2.54         220                    142, [116]{.ul}, [103]{.ul}, [90]{.ul}, [87]{.ul}, 86, [73]{.ul}, 72, [70]{.ul}, [57]{.ul}, [55]{.ul}
         \[Pantothenic acid\]                                       
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------

marinedrugs-18-00367-t006_Table 6

###### 

Identified simple sugars and *R*-cryptone in *Chlorella vulgaris**.*** Underlined *m/z* values indicate intense fragments**.** The table shows peak numbers, corresponding compound name, retention time in minutes (t~R~), parent ion \[M + H\]^+^mass per charge ratio, MS/MS mass per charge ratio of fragment ions.

  Peak   Compound         t~R~ (min)   \[M + H\]^+^ (*m/z*)   MS/MS (*m/z)*
  ------ ---------------- ------------ ---------------------- -------------------------------------------------------------------------------------------------------------
  8      *(R)-*cryptone   5.69         139                    138, 111, 83 53
  10     Glucose          6.54         181                    163, 145, 121, 119, 117, 115, [105]{.ul}, [83]{.ul}, 59, [57]{.ul}, [55]{.ul}
  11     Galactose        7.19         181                    163, 145, [135]{.ul}, 133, [121]{.ul}, 119, 117, 115, [105]{.ul}, 103, [91,]{.ul} 87, 73, [59]{.ul}, 57, 55

marinedrugs-18-00367-t007_Table 7

###### 

Putative annotation of the lipids from ethanol extract of *Chlorella vulgaris**.*** The table shows 48 lipids, their names under each lipid class, molecular formula (MF) and corresponding parent ion \[M + H\]^+^ mass per charge ratio.

  No.   Lipids                                                                                                        MF                  *m/z*
  ----- ------------------------------------------------------------------------------------------------------------- ------------------- -------
        **Diacylglycerophosphoserines**                                                                                                   
  1     1-\[11*Z*,14*Z*-eicosadienoyl\]-2-docosanoyl-glycero-3-phosphoserine                                          C~48~H~90~NO~10~P   872
  2     1-\[11*Z*,14*Z*-eicosadienoyl\]-2-heneicosanoyl-glycero-3-phosphoserine                                       C~47~H~88~NO~10~P   858
  3     1-\[11*Z*,14*Z*-eicosadienoyl\]-2-eicosanoyl-glycero-3-phosphoserine                                          C~46~H~86~NO~10~P   844
  4     1-\[11*Z*-eicosenoyl\]-2-nonadecanoyl-glycero-3-phosphoserine                                                 C~45~H~86~NO~10~P   832
  5     1-\[11*Z*,14*Z*-eicosadienoyl\]-2-nonadecanoyl-glycero-3-phosphoserine                                        C~45~H~84~NO~10~P   830
  6     1-\[11*Z*,14*Z*-eicosadienoyl\]-2-\[9*Z*-nonadecenoyl\]-glycero-3-phosphoserine                               C~45~H~82~NO~10~P   828
  7     1-\[11*Z*,14*Z*-eicosadienoyl\]-2-octadecanoyl-glycero-3-phosphoserine                                        C~44~H~82~NO~10~P   816
  8     1-\[11*Z*,14*Z*-eicosadienoyl\]-2-heptadecanoyl-glycero-3-phosphoserine                                       C~43~H~80~NO~10~P   802
        **Diacylglycerophosphocholines**                                                                                                  
  9     1-octadecanoyl-2-\[11*Z*,14*Z*-eicosadienoyl\]-sn-glycero-3-phosphocholine                                    C~46~H~88~NO~8~P    814
  10    1-octadecanoyl-2-(5Z,11Z,14Z-eicosatrienoyl)-sn-glycero-3-phosphocholine                                      C~46~H~86~NO~8~P    812
  11    1-\[9*Z*-octadecenoyl\]-2-\[9*Z*-nonadecenoyl\]-glycero-3-phosphocholine                                      C~45~H~86~NO~8~P    800
  12    1-octadecanoyl-2-\[9*Z*,12*Z*-heptadecadienoyl\]-glycero-3-phosphocholine                                     C~43~H~82~NO~8~P    772
  13    1-\[9*Z*-octadecenoyl\]-2-\[9*Z*-pentadecenoyl\]-glycero-3-phosphocholine                                     C~41~H~78~NO~8~P    744
  14    1-\[9*Z*-octadecenoyl\]-2-\[9*Z*-tetradecenoyl\]-glycero-3-phosphocholine                                     C~40~H~76~NO~8~P    730
        **Glycosphingolipids**                                                                                                            
  15    *N*-\[eicosanoyl\]-1-beta-lactosyl-sphinganine                                                                C~50~H~97~NO~13~    920
  16    *N*-\[docosanoyl\]-eicosasphinganine-1-phospho-\[1′-myo-inositol\]                                            C~48~H~96~NO~11~P   894
  17    *N*-\[octadecanoyl\]-1-beta-lactosyl-sphinganine                                                              C~48~H~93~NO~13~    892
  18    1-\[11*Z*-eicosenoyl\]-2-\[13*Z*,16*Z*-docosadienoyl\]-glycero-3-phosphocholine                               C~50~H~94~NO~8~P    868
  19    *N*-\[docosanoyl\]-sphinganine-1-phospho-\[1′-myo-inositol\].                                                 C~46~H~92~NO~11~P   866
  20    *N*-\[2-hydroxyheptacosanoyl\]-1-*O*-beta-[d]{.smallcaps}-glucosyl-15-methylhexadecasphing-4-enine            C~50~H~97~NO~9~     856
  21    *N*-hexacosanoyl-1-*O*-beta-D-glucosyl-4-hydroxy-15-methylhexadecasphinganine                                 C~49~H~97~NO~9~     844
  22    *N*-\[2-hydroxyhexacosanoyl\]-1-*O*-beta-[d]{.smallcaps}-glucosyl-15-methylhexadecasphing-4-enine             C~49~H~95~NO~9~     842
  23    *N*-\[2R-hydroxypentacosanoyl\]-1-beta-glucosyl-4E,8*Z*-octadecasphingadienine                                C~49~H~93~NO~9~     840
  24    *N*-\[17*Z*-hexacosenoyl\]-1-beta-glucosyl-sphing-4-enine                                                     C~50~H~95~NO~8~     838
  25    *N*-pentacosanoyl-1-*O*-beta-[d]{.smallcaps}-glucosyl-4-hydroxy-15-methylhexadecasphinganine                  C~48~H~95~NO~9~     830
  26    1-eicosyl-2-eicosyl-sn-glycero-3-phosphocholine                                                               C~48~H~100~NO~6~P   818
  27    *N*-tetracosanoyl-1-*O*-beta-[d]{.smallcaps}-glucosyl-4-hydroxy-15-methylhexadecasphinganine                  C~47~H~93~NO~9~     816
  28    *N*-\[2-hydroxytetracosanoyl\]-1-*O*-beta-[d]{.smallcaps}-glucosyl-15-methylhexadecasphing-4-enine            C~47~H~91~NO~9~     814
  29    *N*-\[15*Z*-tetracosenoyl\]-1-beta-glucosyl-sphinganine                                                       C~48~H~93~NO~8~     812
  30    1-\[3-hydroxyphytanyl\]-2-phytanyl-sn-glycero-3-phosphoethanolamine                                           C~45~H~94~NO~7~P    792
  31    1-octadecyl-2-docosanoyl-sn-glycero-3-phosphoethanolamine                                                     C~45~H~92~NO~7~P    790
  32    1-\[11*Z*,14*Z*-eicosadienoyl\]-2-\[6*Z*,9*Z*,12*Z*-octadecatrienoyl\]-glycero-3-phosphoethanolamine          C~43~H~76~NO~8~P    766
  33    1-\[9*Z*,12*Z*,15*Z*-octadecatrienoyl\]-2-\[8*Z*,11*Z*,14*Z*-eicosatrienoyl\]-glycero-3-phosphoethanolamine   C~43~H~74~NO~8~P    764
  34    *N*-\[2-hydroxyhexacosanoyl\]-4R-hydroxysphinganine                                                           C~44~H~89~NO~5~     712
  35    *N*-\[2-hydroxyheptacosanoyl\]-15-methylhexadecasphing-4-enine                                                C~44~H~87~NO~4~     694
  36    *N*-\[2-hydroxypentacosanoyl\]-15-methylhexadecasphing-4-enine                                                C~42~H~83~NO~4~     666
  37    1,2-Dihexadecyl-sn-glycero-3-phosphoethanolamine                                                              C~37~H~78~NO~6~P    664
  38    *N*-\[2-hydroxy-hexacosanoyl\]-tetradecasphing-4-enine                                                        C~40~H~79~NO~4~     638
  39    1,2-ditetradecyl-sn-glycero-3-phospho-*N*, *N*-dimethylethanolamine                                           C~35~H~74~NO~6~P    636
  40    *N*-\[2R-hydroxyicosanoyl\]-8*Z*-octadecasphingenine                                                          C~38~H~75~NO~4~     610
        **Separate clusters of monoacylglycerophosphoethanolamines and derivatives**                                                      
  41    **(a)** *N*-\[2-hydroxyhexacosanoyl\]-sphinganine                                                             C~44~H~89~NO~4~     696
  42    *N*-\[2R-hydroxyhexadecanoyl\]-4R-hydroxy-20E-hexacosasphingenine                                             C~42~H~83~NO~5~     682
  43    **(b)** *N*-\[2R,3-dihydroxyhexacosanoyl\]-4R-hydroxy-8E-octadecasphingenine.                                 C~44~H~87~NO~6~     726
  44    N-\[2-hydroxyhexacosanoyl\]-4R-hydroxysphinganine                                                             C~44~H~89~NO~5~     712
  45    **(c)** 1-\[11*Z*,14*Z*-eicosadienoyl\]-2-\[9*Z*-tetradecenoyl\]-glycero-3-phospho-\[1′-sn-glycerol\]         C~40~H~73~O~10~P    745
  46    1-\[11*Z*,14*Z*-eicosadienoyl\]-2-dodecanoyl-glycero-3-phospho-\[1′-sn-glycerol\]                             C~38~H~71~O~10~P    719
  47    **(d)** 1-\[11*Z*,14*Z*-eicosadienoyl\]-glycero-3-phosphoethanolamine                                         C~25~H~48~NO~7~P    506
  48    2-\[11*Z*,14*Z*,17*Z*-eicosatrienoyl\]-sn-glycero-3-phosphoethanolamine                                       C~25~H~46~NO~7~P    504
